Payment overview · 2025
General Payments
$2,444.75
74 reported records · 13 companies
Healthcare provider profile · identity verified
David A Sanchez, MD
Allopathic & Osteopathic Physicians|General Practice · SANTA ANA, CA · NPI 1316162258
Verified facts
What the public records show
CMS Open Payments records show David A Sanchez, MD received $2,444.75 in general payments during 2025 across 74 reported records.
Amgen Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Gemtesa, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $475.02 | 19.4% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $458.43 | 18.8% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $368.01 | 15.1% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $290.26 | 11.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $279.69 | 11.4% | 4 | 2025 |
| Botanix SB Inc | Unresolved — no canonical attribution shown | $150.00 | 6.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $143.75 | 5.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.35 | 4.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.16 | 2.2% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $34.48 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.15 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.74 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.71 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,444.75 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $436.19 | 26 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $368.01 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $320.40 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $299.28 | 26 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $290.26 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $258.26 | 7 | 2025 |
Source payment records
|
|||||
| SOFDRA Normalized: sofdra |
Drug | Botanix SB Inc | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $148.85 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $143.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $130.84 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.35 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.16 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $34.48 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 267 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 36 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 439 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
267 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
439 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 439 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 84 |
| Farxiga | Dapagliflozin Propanediol | 267 | 59 |
| Icosapent Ethyl | Icosapent Ethyl | 194 | 56 |
| Vascepa | Icosapent Ethyl | 181 | 42 |
| Losartan Potassium | Losartan Potassium | 171 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 41 |
| Gabapentin | Gabapentin | 130 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 17 |
| Alprazolam | Alprazolam | 97 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 93 | 26 |
| Pregabalin | Pregabalin | 91 | 19 |
| Lisinopril | Lisinopril | 73 | 25 |
| Carvedilol | Carvedilol | 69 | 20 |
| Omeprazole | Omeprazole | 64 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 25 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 62 | 15 |
| Isoniazid | Isoniazid | 61 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 14 |
| Repatha Sureclick | Evolocumab | 48 | 14 |
| Lidocaine | Lidocaine | 43 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 14 |
| Tramadol Hcl | Tramadol Hcl | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 20 |
| Finasteride | Finasteride | 41 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Celecoxib | Celecoxib | 37 | 12 |
| Trazodone Hcl | Trazodone Hcl | 37 | 12 |
| Gemtesa | Vibegron | 36 | 11 |
| Furosemide | Furosemide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 21 |
| Azithromycin | Azithromycin | 28 | 26 |
| Eliquis | Apixaban | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | 11 |
| Belsomra | Suvorexant | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Mupirocin | Mupirocin | 21 | 12 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 13 |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Allopurinol | Allopurinol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,444.75 · 74 records | Amgen Inc. | AIRSUPRA, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, ISTURISA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, SOFDRA, SPRAVATO, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error